C**laims**

1. Use of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of cancer, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof is to be administered in combination with carboplatin, wherein the dose of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof at each treatment event is between 250mg/m^2 and 1250 mg/m^2 and the dose of carboplatin at each treatment event is selected to provide an AUC of between 2 and 5.5 $mgmL^{-1}min^{-1}$, and wherein the combination of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof and the carboplatin results in an increase in amount of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate derived dFdCTP metabolite released intracellularly compared to the amount released intracellularly in the absence of the carboplatin.

2. The use of claim 1, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate in substantially diastereomerically pure form.

3. The use of claim 1, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is a mixture of phosphate diastereoisomers.

4. The use of any one of claims 1 to 3, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is in the form of the free base.

5. The use of any one of claims 1 to 4, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is to be administered intravenously.

6. The use of any one of claims 1 to 5, wherein the cancer is selected from lung cancer, bladder cancer, breast cancer and ovarian cancer.

7. The use of claim 6, wherein the cancer is ovarian cancer.

8. The use of any one of claims 1 to 7, wherein the cancer is relapsed.

9. The use of any one of claims 1 to 8, wherein the cancer is refractory, resistant or partially resistant to carboplatin.

10. The use of any one of claims 1 to 8, wherein the cancer is sensitive or partially sensitive to the carboplatin.

11. The use of any one of the preceding claims, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, is to be administered twice in a 21 day cycle.

12. The use of claim 11, wherein the carboplatin is to be administered once in the 21 day cycle.

13. The use of claim 11 or 12, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, is to be administered on day 1 and day 8 of a 21 day cycle and the carboplatin is to be administered on day 1 of the 21 day cycle.

14. The use of claim 13, wherein the gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, or a pharmaceutically acceptable salt or solvate thereof, and the carboplatin are to be administered simultaneously on day 1 of the 21 day cycle.